Roche gets EMA rec­om­men­da­tion for Ocre­vus; An­them now cov­ers Sarep­ta's ex­on-skip­ping Duchenne MD drug

→ The EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use has giv­en a glow­ing rec­om­men­da­tion for Roche’s mul­ti­ple scle­ro­sis drug Ocre­vus (ocre­lizum­ab), paving the way …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER